Valeritas Holdings, Inc. (VLRX) Receives Consensus Recommendation of “Strong Buy” from Analysts

Shares of Valeritas Holdings, Inc. (NASDAQ:VLRX) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Brokers have set a twelve-month consensus price target of $13.50 for the company, according to Zacks. Zacks has also given Valeritas an industry rank of 178 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

Separately, ValuEngine raised shares of Valeritas from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st.

Shares of VLRX stock opened at $3.00 on Wednesday. Valeritas has a 1-year low of $2.00 and a 1-year high of $13.00. The stock has a market cap of $20.95, a price-to-earnings ratio of -0.22 and a beta of 4.91. The company has a current ratio of 3.02, a quick ratio of 2.40 and a debt-to-equity ratio of -8.88.

COPYRIGHT VIOLATION NOTICE: “Valeritas Holdings, Inc. (VLRX) Receives Consensus Recommendation of “Strong Buy” from Analysts” was originally reported by Macon Daily and is owned by of Macon Daily. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://macondaily.com/2018/04/12/valeritas-holdings-inc-vlrx-receives-consensus-recommendation-of-strong-buy-from-analysts-updated-updated-updated.html.

About Valeritas

Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.

Get a free copy of the Zacks research report on Valeritas (VLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply